Jamie Kang

[Humacyte, Inc.] Humacyte, Inc. announced that the FDA has accepted its Investigational New Drug application (IND) for a first-in-human clinical study of the coronary tissue engineered vessel (CTEV) in coronary artery bypass grafting. The CTEV is a universally implantable bioengineered human blood vessel.

[Cancer Discovery] Tracing the transcriptional response of liver metastasis–associated peritumoral and tumor endothelial cells (TEC) to T cell intervention, scientists discovered an immunomodulatory TEC subpopulation that highly expressed lipoprotein lipase (LPL).

[Science Advances] Investigators hypothesized that sphingosine-1-phosphate (S1P) reduces platelet adhesion and thrombus formation by up-regulation of endothelial thrombomodulin. This would identify S1P as an antithrombotic target without increasing bleeding risk.

[Pharmacological Research] Researchers uncovered a novel pathogenic axis in liver sinusoidal microthrombosis formation, where COX-2 drives a prothrombotic switch in liver sinusoidal endothelial cells via AKT/mTOR-mediated metabolic reprogramming and lactate-dependent epigenetic upregulation of thrombospondin-1 (TSP-1).

[GeroScience] Investigators tested the hypothesis that circulating factors derived from humans practicing time-restricted eating induce protective and adaptive responses in human cerebromicrovascular endothelial cells.

[Tissue Engineering Part A] Scientists developed a novel organ-on-a-chip model that integrated human JEG-3 trophoblast organoids with human umbilical vein endothelial cells under combined fluid shear stress and mechanical strain. This configuration supported the self-assembly of a three-dimensional, functional placental barrier.